Smith & Nephew plc (SN.L) – What Are Analysts Saying About This Stock?

Smith & Nephew plc (LON:SN) has earned a consensus rating of “Hold” from the nine analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is GBX 1,255.

A number of research firms have issued reports on SN. Berenberg Bank decreased their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a report on Friday, August 14th. Citigroup lowered shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,250 target price on shares of Smith & Nephew in a research report on Tuesday, September 15th. JPMorgan Chase & Co. reduced their target price on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada reduced their target price on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research note on Thursday, August 6th.

Smith & Nephew Trading Up 6.5%

LON:SN opened at GBX 1,190 on Thursday. The stock has a market cap of £13.05 billion, a P/E ratio of 42.84, a PEG ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The stock’s fifty day moving average is GBX 1,053.81 and its 200 day moving average is GBX 1,152.03.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.